Presentation Highlights CD2 as an Optimal Costimulatory Target Demonstrates Durable in vivo Anti-Tumor Efficacy with EVOLVEīRANFORD, CT – Octo– EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy.
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and ImmunotherapyĮVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies
0 kommentar(er)
